BMY Bristol Myers Squibb Co

Bristol-Myers Squibb Company (BMY) is currently at $62.58, up $0.48 or 0.78%

-- Would be highest close since Oct. 9, 2018, when it closed at $63.23

-- Currently up 10 of the past 11 days

-- On Tuesday, presented survival and safety data from its study evaluating CC-486 as maintenance therapy in a broad population of patients with front-line, newly diagnosed acute myeloid leukemia. In the QUAZAR AML-001 study, treatment with CC-486 in the maintenance setting provided patients a statistically significant and clinically meaningful improvement. Based on the results, Bristol-Myers Squibb said it is planning regulatory submissions in the first half of 2020

-- Currently up eight consecutive days; up 9.9% over this period

-- Longest winning streak since Aug. 31, 2017, when it rose for nine straight trading days

-- Best eight day stretch since the eight days ending Jan. 15, 2019, when it rose 10.2%

-- Up 9.9% month-to-date

-- Up 20.38% year-to-date; on pace for best year since 2013, when it rose 63.09%

-- Down 18.49% from its all-time closing high of $76.77 on July 14, 2016

-- Up 17.09% from 52 weeks ago (Dec. 12, 2018), when it closed at $53.44

-- Would be a new 52 week closing high

-- Up 46.31% from its 52 week closing low of $42.77 on July 22, 2019

-- Traded as high as $62.98; highest intraday level since Oct. 10, 2018, when it hit $63.35

-- Up 1.43% at today's intraday high

All data as of 10:55:09 AM

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

December 11, 2019 11:18 ET (16:18 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.